ArticleJournal of clinical laboratory analysis2026
Impact of Anemia and Comorbidity Burden on Disease Progression and Outcomes in Chronic Kidney Disease.
Article in Journal of clinical laboratory analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic kidney disease progression is influenced by anemia and comorbidities; however, the possibility of a real effect of these two phenomena has hardly been the subject of research.
objectiveThe present study set out to evaluate the association between anemia and burden of comorbidities on CKD progression and hospitalizations over 1 year.
methodsA retrospective study involving 120 adult CKD patients. Anemia was defined as hemoglobin < 13 g/dL in males and < 12 g/dL in females while comorbidity burden was defined by a simple comorbidity index: hypertension, diabetes, and cardiovascular disease. CKD progression was coded as a ≥ 25% decline in eGFR or stage conversion. Multivariate logistic regression identified predictors of hospitalization.
resultsParticipants' mean age was 58.3 years, and 53.3% were males. Anemia was present in 67.5% of the cases, and 33.3% had two or more comorbidities. CKD progression was seen in 43.3% at 1 year; patients with anemia and two or more comorbidities showed the highest progression rate at 77.5% (p < 0.001). Progressors had significantly lower hemoglobin and higher RDW values. Hospitalization was documented in 29.2%, and anemia independently predicted hospitalization (OR 3.4); comorbidity index ≥ 2 (OR 2.8), and RDW > 14.5% (OR 2.6). Each 1 g/dL increase in hemoglobin reduced hospitalization risk by 28% (OR 0.72).
conclusionAnemia and multiple comorbidities jointly increased the risk of CKD progression and hospitalization. Routine hematological parameters along with assessing comorbidities might have a role to play in early risk stratification and guiding focused interventions in CKD management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.